$470,000 Loss Posted by Blood Products Maker
- Share via
HemaCare Corp., a Sherman Oaks provider of specialty blood products and services, reported a loss of $470,000 for the first quarter compared with a profit of $21,000 a year earlier.
HemaCare’s revenue was up 5% for the three months that ended March 31, to $3.33 million from $3.18 million.
The company attributed the loss to research and development expenses related to its experimental treatment for AIDS, called passive hyperimmune therapy.
HemaCare is awaiting approval from the state to continue the next phase of clinical study.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
